Time Course and Clinical Implications of Development of Antibodies Against Adalimumab in Patients With Inflammatory Bowel Disease.

Background:Antibodies (Abs) against adalimumab (ADL) have been associated with low ADL levels and treatment failure.Aim:To characterize the temporal characteristics of anti-ADL Ab appearance and possible disappearance, and determine the clinical significance on drug efficacy and disease course.Metho